Compare LUMN & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUMN | ICLR |
|---|---|---|
| Founded | 1968 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 9.3B |
| IPO Year | 1994 | 2001 |
| Metric | LUMN | ICLR |
|---|---|---|
| Price | $8.02 | $159.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $7.25 | ★ $178.62 |
| AVG Volume (30 Days) | ★ 12.9M | 1.2M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,402,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.91 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.37 | $66.57 |
| 52 Week High | $11.95 | $211.00 |
| Indicator | LUMN | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 68.40 |
| Support Level | $7.40 | $156.94 |
| Resistance Level | $8.42 | $189.37 |
| Average True Range (ATR) | 0.51 | 7.17 |
| MACD | -0.15 | -0.37 |
| Stochastic Oscillator | 18.61 | 90.61 |
Lumen Technologies is one of the largest telecommunications carriers serving global enterprises. The merger with Level 3 in 2017, the 2022 divestiture of much of its local phone business in rural areas, and the 2026 sale of its remaining consumer fiber network to AT&T have shifted the company's operations away from the legacy consumer business and toward enterprise services, which account for about 85%-90% of revenue. Lumen offers businesses a full suite of communications services, providing colocation and data center services, data transportation, phone service, and internet access.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.